¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mantle cell lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
¿µ¹® stem cell ÇÑ±Û Áٱ⼼Æ÷, °£¼¼Æ÷
¼³¸í   
  Àڱ⠺¹Á¦¸¦ ÇÏ¿© ÀÚ½ÅÀ» Á¸¼Ó½ÃŰ¸é¼­ ÇÑÆíÀ¸·Î´Â Áõ½Ä°ú ºÐÈ­¸¦ ÇÏ¿© »õ·Î¿î ¼¼Æ÷¸¦ Çü¼ºÇϴ ¼¼Æ÷·Î¼­ Á¶Ç÷Áٱ⼼Æ÷°¡ ´ëÇ¥ÀûÀÌ´Ù. Á¶Ç÷Áٱ⼼Æ÷´Â °ñ¼ö¿¡ Àִ ¼¼Æ÷·Î¼­ ¸ðµç Ç÷±¸¼¼Æ÷°¡ ¿©±â¿¡¼­ ºÐÈ­µÇ¾î ¹ß»ýÇÑ´Ù.
¿µ¹® renal cell carcinoma ÇÑ±Û ÄáÆÏ¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÄáÆÏ¿¡ »ý±ä ¿ø½ÃÄáÆÏÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ ¾Ï. ÁַΠ¿ø½Ã¼¼´¢°üÁ¶Á÷¿¡¼­ ¹ß»ýÇÑ´Ù. ´ëÇ¥ÀûÀΠ¼¼Æ÷Á¶Á÷ÇüÀº ¿°»ö½Ã ¼¼Æ÷ÁúÀÌ ¸¼°Ô ºñ¾îº¸À̴ ¸¼Àº¼¼Æ÷¾ÏÁ¾ÀÌ´Ù. Ä¡·á´Â ¼ö¼ú°ú Ç×¾ÏÈ­Çпä¹ýÀ̸砾ÆÁÖ µå¹°Áö¸¸ ÀúÀý·Î ³´´Â °æ¿ìµµ Àִ °ÍÀ¸·Î º¸°íµÇ¾î ÀÖ´Ù.
¿µ¹® squamous cell carcinoma ÇÑ±Û ÆíÆò¼¼Æ÷¾ÏÁ¾
¼³¸í   
  ÆíÆò¼¼Æ÷ ±â¿øÀÇ ¾ÏÀ¸·Î¼­, ÆíÆò¼¼Æ÷°¡ Àִ ¾î¶² °÷¿¡¼­µç ¹ß»ý°¡´ÉÇÔ. µû¶ó¼­ ½Äµµ¾Ï, ÇǺξÏ, Æó¾Ï, ÀڱþϠµîÀÌ ¿©±â¿¡ ÇØ´çµÈ´Ù. Æ¯È÷ ÇǺξÏÀº ¸¹Àº Àڿܼ±Á¶»ç¿¡ ÀÇÇØ »ý±â´Â ±¤¼±°¢È­Áõ¿¡¼­ ¹ß»ý°¡´ÉÇÏ´Ù. º´¸®Á¶Á÷ÇÐÀû Æ¯¼ºÀ¸·Î¼­ °¢ÁúÀ» »ý¼ºÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • acidophilic cell
    È£»ê¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷, ¼¼¿±¼¼Æ÷
  • acinar cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • acinic cell carcinoma
    »ù²Ê¸®¼¼Æ÷¾ÏÁ¾, ¼¼¿±¼¼Æ÷¾ÏÁ¾
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell adenoma
    ¹Ù´Ú¼¼Æ÷»ùÁ¾, ±âÀú¼¼Æ÷¼±Á¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • packed red blood cell
    ³óÃàÀûÇ÷±¸
  • parietal cell
    º®¼¼Æ÷
  • perivascular cell
    Ç÷°üÁÖÀ§¼¼Æ÷
  • plasma cell
    ÇüÁú¼¼Æ÷
  • polynucleated cell
    ¹µÇÙ¼¼Æ÷
  • prickle cell
    °¡½Ã¼¼Æ÷
  • principal cell
    ÁÖ¼¼Æ÷, À¸¶ä¼¼Æ÷
  • Purkinje cell
    1. ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷, 2. Á¶·Õ¹Ú¼¼Æ÷
  • pyramidal cell
    ÇǶó¹Ìµå¼¼Æ÷
  • red blood cell
    ÀûÇ÷±¸
  • reserve cell
    ¿¹ºñ¼¼Æ÷
  • resting cell
    ÈÞÁö±â¼¼Æ÷, Á¤Áö¼¼Æ÷
  • reticuloendothelial cell
    ±×¹°³»ÇǼ¼Æ÷, ¼¼¸Á³»ÇǼ¼Æ÷
  • rod cell
    ¸·´ë¼¼Æ÷
  • round cell
    ¿øÇü¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • argentaffin cell
    ģũ·ÒÀº¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • basal cell adenoma
    ±âÀú¼¼Æ÷»ùÁ¾, ¹Ù´Ú¼¼Æ÷¾ÏÁ¾
  • basosqumaous cell acanthoma
    ±âÀúÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • cell-associated antibody
    ¼¼Æ÷ºÎÂøÇ×ü
  • cell-bound antibody
    (¢¡cell-fixed antibody) ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾
  • crescent cell anemia
    Ãʽ´ÞÀûÇ÷±¸ºóÇ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷´É, Á¶·Â¼¼Æ÷´É
  • islet cell adenoma
    ¼¶¼¼Æ÷»ùÁ¾
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • red cell aplasia
    ÀûÇ÷±¸¹«Çü¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • HeLa cell
    Çï¶ó¼¼Æ÷.
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • Heidenhain s cell
    ÇÏÀ̵§ÇÏÀμ¼Æ÷.
  • Henle s cell
    Çî·¯¼¼Æ÷.
  • Hfr cell
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷
  • Hulle cell
    ¿ÜÇǼ¼Æ÷
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • K cell
    K¼¼Æ÷, »ìÇØ¼¼Æ÷
  • LE cell
    LE¼¼Æ÷.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • giant follicular lymphoma
    °Å´ë¿©Æ÷¼º ¸²ÇÁÁ¾.
  • histiocytic lymphoma
    Á¶Á÷±¸¸²ÇÁÁ¾
  • immunoblastic lymphoma
    ¸é¿ª ¸ð¼¼Æ÷ ¸²ÇÁÁ¾
  • intestinal lymphoma
    À帲ÇÁÁ¾.
  • leukemia/lymphoma
    ¹éÇ÷º´/¸²ÇÁÁ¾(ÛÜúìÜ»/¡­ðþ)
  • lymphoepithelioid lymphoma
    ¸²ÇÁÇ¥ÇÇ¾ç ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾.
  • lymphoma
    ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma cells
    ¸²ÇÁÁ¾¼¼Æ÷(¡­á¬øà)
  • lymphoma, Burkitts
    ¹öŶƮ ¸²ÇÁÁ¾
  • lymphoma,burkitts
    ¹öŶ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma,follicular
    ¿©Æ÷¼º¸²ÇÁÁ¾(æ¤øààõ¡­ðþ)
  • lymphoma,lymphoblastic
    ¸²ÇÁ¸ð±¸¼º ¸²ÇÁÁ¾(¡­Ù½Ï¹àõ ¡­)
  • lymphoma,lymphocytic
    ¸²ÇÁ±¸¼º(¡­Ï¹àõ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Theca lutein cell
    ³­Æ÷¸·È²(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] ³­Æ÷¸·È²Ã¼¼¼Æ÷
  • Follicular cell
    ³­Æ÷¼¼Æ÷
    [¿¾ ¿ë¾î] ³­Æ÷¼¼Æ÷
  • Endothelial cell
    ³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ³»ÇǼ¼Æ÷
  • Ependymal cell
    ³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] »óÀǼ¼Æ÷
  • Secretory cell of lacrimal gland
    ´«¹°¼¼Æ÷
    [¿¾ ¿ë¾î] ´©¼±¼¼Æ÷
  • Delta cell
    µ¨Å¸¼¼Æ÷
    [¿¾ ¿ë¾î] µ¨Å¸¼¼Æ÷
  • Fat-storing cell
    µ¿±¼ÁÖÀ§Áö¹æ¼¼Æ÷
    [¿¾ ¿ë¾î] µ¿¾çÇ÷°üÁÖÀ§Áö¹æ¼¼Æ÷
  • Bipolar cell
    µÎ±Ø¼¼Æ÷
    [¿¾ ¿ë¾î] ¾ç±Ø¼¼Æ÷
  • Spherical cell
    µÕ±Ù¼¼Æ÷
    [¿¾ ¿ë¾î] ±¸Çü¼¼Æ÷
  • Glial cell of peripheral nervous system
    ¸»ÃʾƱ³¼¼Æ÷
    [¿¾ ¿ë¾î] ¸»Ãʱ³¼¼Æ÷
  • Choroid ependymal cell
    ¸Æ¶ô³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¸Æ¶ô»óÀǼ¼Æ÷
  • Dust cell
    ¸ÕÁö¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ÕÁö¼¼Æ÷
  • Amacrine cell
    ¹«Ãà»è¼¼Æ÷
    [¿¾ ¿ë¾î] ¹«Ãà»è¼¼Æ÷
  • Polyhedral cell
    ¹µ¸éü¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù°¢Çü¼¼Æ÷
  • Polyhedral cell
    ¹µ¸éü¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ù¸éü¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • centrifuge cell
    ¿ø½ÉºÐ¸®½Ç(êÀãýÝÂ×îãø)
  • competent cell
    Àû°Ý¼¼Æ÷(îêÌ«á¬øà)
  • constitutive secretory cell
    ±¸¼º¼º ºÐºñ¼¼Æ÷(ϰà÷àõÝÂÝôá¬øà)
  • continuous cell line
    "Áö¼Ó¼¼Æ÷ÁÖ(ò¥áÙá¬øàñ»), (ÔÒ) established cell line"
  • COS cell
    COS ¼¼Æ÷(á¬øà)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • double-sector cell
    ÀÌÁß±¸È¹½Ç(ì£ñìÏ¡üñãø)
  • effector cell
    È¿°ú±â ¼¼Æ÷(üùÍýÐïá¬øà)
  • enucleated cell
    Á¦ÇÙ ¼¼Æ÷ (ð¶ú·á¬øà)
  • established cell line
    ¼ö¸³ ¼¼Æ÷ÁÖ (â§Ø¡á¬øàñ»)
  • feeder cell
    °ø±ÞÀÚ¼¼Æ÷ (ÍêÐåíºá¬øà)
  • flow cell
    È帧 ½Ç(ãø)
  • founder cell
    ½ÃÁ¶ ¼¼Æ÷(ã·ðÓá¬øà)
  • germ cell
    ¹è¼¼Æ÷(ÛÏá¬øà)
  • germinal cell
    ¹è¾Æ¼¼Æ÷(ÛÏä´á¬øà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • goblet cell
    ¼úÀܼ¼Æ÷, ¹è³¶¼¼Æ÷
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼Æ÷Á¾
  • granulosa cell
    °ú¸³¸·¼¼Æ÷
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • islet cell
    µµ¼¼Æ÷
  • islet cell adenoma
    Ãéµµ¼¼Æ÷¼±Á¾
  • islet cell carcinoma
    µµ¼¼Æ÷¾ÏÁ¾
  • Langerhans' cell
    ¶û°Ô¸£Çѽº¼¼Æ÷
  • Langhans' glant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • large cell
    ´ë¼¼Æ÷
  • lymphoid cell
    ¸²ÇÁ¾ç¼¼Æ÷, ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ±¸¾ç¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    À¯µ¹ºÀ¼Ò
  • mastoid cell
    À¯(¾ç)µ¹(±â)ºÀ¼Ò
  • nerve cell
    ½Å°æ¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CTCL Cutaneous T Cell Lymphoma
ATCL adult T-cell leukemia or lymphoma
ATLL adult T-cell leukemia/lymphoma
BCL basic cycle length; B-cell leukemia/lymphoma
BLCL Burkitt lymphoma cell line
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CBCL Cutaneous B cell lymphoma
CTCL Cutaneous T cell lymphoma
DLBCL Diffuse Large B-cell Lymphoma
DLBL Diffuse large B cell lymphoma
HTLV-I Human T cell leukemia-lymphoma virus type I
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lymphoma, T-cell A group of heterogeneous lymphoid tumours representing malignant transformations of T-lymphocytes.
(12 Dec 1998)
lymphoma, T-cell, cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. Mycosis fungoides and sezary syndrome are the best characterised of these disorders.
(12 Dec 1998)
lymphoma, T-cell, peripheral A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (lymphoma, large-cell, immunoblastic), this group's unique features warrant separate treatment.
(12 Dec 1998)
benign lymphoma of the rectum A rectal polyp composed of lymphoid tissue with follicle formation, covered by mucosa.
(05 Mar 2000)
burkitt lymphoma A form of undifferentiated malignant lymphoma usually found in central africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumour in virtually all cases of burkitt lymphoma. The epstein-barr virus (herpes virus 4, human) has been isolated from burkitt lymphoma cases in africa and it is implicated as the causative agent in these cases; however, most non-african cases are ebv-negative.
(12 Dec 1998)
Burkitt's lymphoma <oncology, tumour> A type of Non-Hodgkin lymphoma that most often occurs in young people between the ages of 12 and 30. The disease usually causes a rapidly growing tumour in the abdomen.
(12 May 1997)
cancer, lymphoma, hodgkin's A type of lymphoma (cancer of the lymphatic system). The most common symptom of Hodgkin's disease is a painless swelling in the lymph nodes in the neck, underarm, or groin. Hodgkin's disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. Treatment usually includes radiation therapy or chemotherapy. Regular follow-up examinations are important after treatment for Hodgkin's disease. Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukaemia.
(12 Dec 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
canine malignant lymphoma <tumour> A progressive fatal disease of dogs characterised by neoplastic transformation and proliferation of lymphoid cells, usually originating in solid lymphoid organs (lymphosarcoma) or bone marrow (lymphocytic leukaemia).
(05 Mar 2000)
malignant lymphoma <tumour> A general term for ordinarily malignant neoplasms of lymphoid and reticuloendothelial tissues which present as apparently circumscribed solid tumours composed of cells that appear primitive or resemble lymphocytes, plasma cells, or histiocytes. Lymphomas appear most frequently in lymph nodes, spleen, or other normal sites of lymphoreticular cells; when disseminated, Lymphoma's, especially of the lymphocytic type, may invade the peripheral blood and manifest as leukaemia. Lymphomas are classified by cell type, degrees of differentiation, and nodular or diffuse pattern; Hodgkin's disease and Burkitt's lymphoma are special forms.
(05 Mar 2000)
Mediterranean lymphoma A spectrum of conditions ranging from a benign plasma cell hyperplasia to a highly malignant lymphoma of the small intestine.
(12 Dec 1998)
well-differentiated lymphocytic lymphoma <tumour> Essentially the same disease as chronic lymphocytic leukaemia, except that lymphocytes are not increased in the peripheral blood; lymph nodes are enlarged and other lymphoid tissue or bone marrow is infiltrated by small lymphocytes.
Synonym: small lymphocytic lymphoma.
(05 Mar 2000)
poorly differentiated lymphocytic lymphoma <tumour> A B-cell lymphoma with nodular or diffuse lymph node or bone marrow involvement by large lymphoid cells.
Synonym: follicular predominantly small cleaved cell lymphoma, nodular histiocytic lymphoma.
(05 Mar 2000)
histiocytic lymphoma <tumour> A malignant tumour of reticular tissue composed predominantly of neoplastic histiocytes.
See: large cell lymphoma.
(05 Mar 2000)
Hodgkin's lymphoma <haematology, oncology> A human malgnant disorder of lymph tissue (lymphoma) that appears to originate in a particular lymph node and later spreads to the spleen, liver and bone marrow. It occurs mostly in individuals between the ages of 15 and 35. It is characterised by progressive, painless enlargement of the lymph nodes, spleen and general lymph tissue.
Giant cells, the Reed Sternberg cells, with mirror image nuclei are diagnostic. Immunological depletion, caused perhaps by the excessive growth of neoplastic histiocytes, occurs.
Four types of the disease are recognised depending on the relative predominance of various neoplastic derivatives of the lymphoid series. Pyrexia is often a feature of the disease.
Death often results from generalised immunological inability to respond to infections. If detected early, it has a high remission rate.
Staging: Ann Arbor classification; each stage is further classified as:, A no symptoms, B fever, sweats, weight loss.
Stage I - involvement of a single lymph-node region or extralymphatic site.
Stage II - two or more sites of involvement on the same side of the diaphragm.
Stage III - disease involvement on both sides of the diaphragm.
Stage IV - disseminated disease of extralymphatic organs, with or without lymph-node involvement.
Indicence: approximately 1,500 new cases per year in the UK.
(30 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • germ cell
    »ý½Ä ¼¼Æ÷
  • guard cell
    °øº¯¼¼Æ÷
  • hair cell
    À¯¸ð ¼¼Æ÷(ƯÈ÷ ÄÚ¸£Æ¼ ±â°ü µî¿¡ Àִ û°¢ ¼¼Æ÷)
  • hot cell
    ¹æ»ç¼º ¹°Áú 󸮿ë Â÷Æó½Ç
  • interstitial cell stimulating hormone
    °£¼¼Æ÷ ÀÚ±Ø È£¸£¸ó(ICSH)
  • memory cell
    (ÄÄÇ»ÅÍ)±â¾ï¼ÒÀÚ
  • mercuer cell
    ¼öÀº ÀüÁö
  • micelle,-cell
    ±³Áú ÀÔÀÚ;¹Ì¼¿
  • microbial cell
    ¹Ì»ý¹°ÀÇ ±Õü
  • narrow bed(cell)
    NARROW HOUSE
  • nerve cell
    ½Å°æ¼¼Æ÷
  • padded cell
    (´ÙÄ¡Áö ¾Ê°Ô º®¿¡ ÆÐµå¸¦ ´í)Á¤½Å º´¿ø ȯÀÚ½Ç
  • photoelectric cell
    ±¤ÀüÁö;±¤Àü°ü 9
  • photoelectrochemical cell
    °í¾ÆÀü±â È­ÇÐ ÀüÁö
  • porous cell(cup)
    Ãʹú±¸ÀÌ Àڱ⠿ë±â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á